Newsroom
Sorted by: Latest
-
TemperPack Launches New Mailer to Replace Boxes for E-Commerce Shippers
RICHMOND, Va.--(BUSINESS WIRE)--TemperPack today announced the launch of its recyclable padded mailer, a high-performance solution designed to allow e-commerce brands to switch away from boxes for wide range of items. The new structure opens wider, packs faster, and protects better than traditional mailers, for greater capacity, cushioning, and ease of operation. TemperPack’s mailer uses WaveKraft engineered material, a unique paper-based substrate designed to offer 50% to 80% better cushioning...
-
Pershing Square Announces Launch of the Combined IPO of Pershing Square USA and Pershing Square Inc.
NEW YORK--(BUSINESS WIRE)--Pershing Square USA, Ltd. (“PSUS”), a closed end investment company to be managed by Pershing Square Capital Management, L.P. (“PSCM”) and Pershing Square Inc. (“PSI”), the prospective parent company of PSCM, today announced the launch of the initial public offering (the “PSUS IPO”) of the common shares of beneficial interest of PSUS (the “PSUS Shares”) and the initial public offering (the “PSI IPO”, and together with the PSUS IPO, the “Combined IPO”) of the common st...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 10.04.2026 FVD. IE00BKVKW020 250,002.00 USD 7,315,704.28 29.263 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 10.04.2026 FCSG IE00BKPSPT20 1,025,002.00 USD 43,709,558.12 42.643 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 10.04.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 762,208.69 27.010 ...
-
Constellation Kidney Group Expands KidneyOne™, Its Integrated Platform for Kidney Care Providers, with Launch of RCM Intelligence
RICHMOND, Va.--(BUSINESS WIRE)--April 13, 2026--Constellation Kidney Group (CKG), a leading technology provider for dialysis organizations, today announced the launch of RCM Intelligence, a new analytics capability that expands the KidneyOne™ platform, CKG’s integrated operating system for kidney care providers. RCM Intelligence strengthens the CKG Intelligence data and AI layer that powers analytics across the platform and transforms dialysis billing data into actionable operational insights....
-
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026....
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 10.04.2026 FTFX IE00BD5HBQ97 63,402.00 USD 1,684,174.26 26.563 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 10.04.2026 FJUL.LN IE000YJBT6I5 100,002.00 USD 2,702,848.71 27.028 ...
-
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial wil...